Abstract
Natural killer (NK) cells have the potential to be effective killers of tumor cells. They are governed by inhibitory and activating receptors like NKG2D, whose ligands are normally upregulated in cells that are stressed, like cancer cells. Advanced cancer cells, however, have ways to reduce these ligands’ expression, leaving them less detectable by NK cells. Along with these receptors, NK cells also require activating cytokines, like interleukin 12 (IL-12). The goal of this study is to develop a novel bi-functional fusion protein for enhanced NK cell activation. The proposed protein combines the extracellular domain of the NKG2D ligand Mouse UL-16-binding protein-like transcript 1 (MULT1E) and mouse IL-12 (mIL-12). It is hypothesized that when expressed by tumor cells, the protein will activate NK and other killer cells using the NKG2D receptor, and deliver mIL-12 to the NK cells where it can interact with the IL-12R and enhance cytotoxicity. The fusion protein, when expressed by engineered tumor cells, indeed activated NK cells in vitro as assayed by increased production of interferon-γ and cytotoxicity and significantly reduced tumor growth in vivo. Although the study is preliminary, the data suggest that the MULT1E/mIL-12 bi-functional fusion protein is an effective activator of NK cells for cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berke G . The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994; 12: 735–773.
Salih HR, Rammensee H-G, Steinle A . Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098–4102.
Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM . Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002; 169: 4079–4083.
Diefenbach A, Hsia JK, Hsiung MY, Raulet DH . A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003; 33: 381–391.
Nice TJ, Coscoy L, Raulet DH . Posttranslational regulation of the NKG2D ligand MULT1 in response to cell stress. J Exp Med 2009; 206: 287–298.
Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779–788.
Zhu L, Zhao Z, Wei Y, Marcotte W, Wagner T, Yu X . An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation. Int J Oncol 2012; 41: 659–667.
Brunda MJ, Luistro L, Warrier RB, Hubbard BR, Murphy M, Wolf SF et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223–1230.
Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581–586.
Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L . Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239–252.
Perou CM, Moore KJ, Nagle DL, Misumi DJ, Woolf EA, McGrail SH et al. Identification of the murine beige gene by YAC complementation and positional cloning. Nat Genet 1996; 13: 303–308.
Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J . Gene therapy clinical trials worldwide to 2012–an update. J Gene Med 2013; 15: 65–77.
Kotturi HS, Li J, Branham-O’Connor M, Yu X, Wagner TE, Wei Y . In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors. Cancer Gene Therapy 2010; 17: 164–170.
Schmittgen TD, Livak KJ . Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101.
Acknowledgements
We thank Robert Borucki for constructing and characterizing the MULT/6 clone. The work was partially supported by the Greenville Hospital System (GHS) Oncology Research Foundation and a grant from Clemson University Research Grant Committee (URGC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Tietje, A., Li, J., Yu, X. et al. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation. Gene Ther 21, 468–475 (2014). https://doi.org/10.1038/gt.2014.15
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2014.15